Trials / Completed
CompletedNCT01967810
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 73 (actual)
- Sponsor
- Angiochem Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in patients with high-grade glioma. Another purpose of this study is to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of ANG1005 in patients.
Detailed description
See above.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ANG1005 | ANG1005 at a starting dose of 650 mg/m\^2 or 600 mg/m\^2 by intravenous infusion once every 3 weeks |
| DRUG | Bevacizumab | For participants enrolled in the bevacizumab-refractory recurrent GBM arm (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion. |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2016-02-01
- Completion
- 2017-09-01
- First posted
- 2013-10-23
- Last updated
- 2020-02-25
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01967810. Inclusion in this directory is not an endorsement.